carmustine has been researched along with arsenic trioxide in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y | 1 |
Chang, JY; Chen, KL; Chen, LT; Chen, SN; Cheng, YT; Kuo, CC; Liu, JF; Liu, TW; Pan, WY; Shiah, HS; Wu, CM; Yang, YN | 1 |
2 other study(ies) available for carmustine and arsenic trioxide
Article | Year |
---|---|
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine | 2007 |
Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Carmustine; Cell Death; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Glutathione; Glutathione Reductase; Humans; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |